Glutathione, injectable

Glutathione is three of the building blocks the body uses to make proteins, joined end to end: glutamate, cysteine and glycine. A short chain like that is called a peptide, and unlike almost everything else in this reference, your own body already makes this one, by the gram, in your liver. There is no medicine approved in the United States whose active ingredient is glutathione. I searched the Food and Drug Administration's approved drug database by active ingredient and got back an eye irrigation solution and a methotrexate record, neither of them a glutathione product. What a clinic hangs in the bag is compounded, mixed to order by a pharmacy rather than manufactured as an approved drug, and the compounding pharmacy's own page says the regulator has not evaluated that formulation for safety or effectiveness. It is an approved injectable in some other countries, in the Philippines as an add on to cisplatin chemotherapy and, Sonthalia and colleagues report, in India for liver disorders.

Two different mechanisms get claimed for it and they should not be run together. For skin, the idea is that it switches off tyrosinase, the enzyme at the top of the pathway that makes pigment, by binding the copper at that enzyme's working end, and that it pushes the body away from making the brown black pigment toward making the red yellow one. There is a hole in the middle of that: to switch the enzyme off, the molecule has to get inside the little sac where pigment is made, and Sonthalia and colleagues report no channel and no diffusion route for it. In cells in a dish, as Sonthalia reports Chung's work, glutathione itself did not inhibit the enzyme inside the cell and two chemically altered versions of it did. For everything else the drip gets sold for, glutathione is the cell's main antioxidant inside the cell, which is uncontroversial biology. The step that has to be true for an infusion to matter is that what goes into a vein ends up inside cells, and the regulator's own review says it does not easily cross into the brain. It is like watering a houseplant down the outside of the pot: you can measure the water going in, and I could find nobody who has dug down to see whether any of it reached the roots.

It gets sold for two different things. One is lightening skin. The other is the general wellness drip, where a Los Angeles infusion clinic's own page offers it to support liver function, cellular health, skin clarity, immune resilience and recovery from oxidative stress, and cites no studies of any kind. The regulator assessed glutathione against 24 nominated uses at once, human, all routes, from cystic fibrosis to septic shock, and found either no information or insufficient evidence of effectiveness for every one of them, adding that some evidence may support skin lightening but that no specific population or dose has been established. That is what it is sold and talked about for, not what it has been shown to do.

The whole case for putting it in a vein is that swallowing it does not work, and that rests on one dose given to seven people who were then watched for four and a half hours. Look for longer and the answer changes: a randomised placebo controlled trial of capsules at a trial dose of 1,000 mg a day for six months, and not as a recommendation, with 54 adults analysed, finished 30 to 35 percent up in red cells, plasma and lymphocytes, while a four week trial at the same daily amount in 40 adults found nothing move. The trade quotes the four and a half hour study, and I found no clinic page mentioning the six month one. The regulator, having read all of it, still concluded that the amount of swallowed glutathione that reaches the bloodstream is minimal, so the two readings sit side by side rather than one having settled the other.

The one skin lightening trial that FDA's literature search and mine both found is also the harm record. Of the 25 healthy women who received glutathione over six weeks, every one reported a side effect and nobody on salt water did, and nine stopped early for severe adverse effects, eight of them because their liver tests went wrong and one for anaphylaxis, a whole body allergic reaction that can close the airway. FDA's adverse event database held 17 reports across twenty two years, seven of them anaphylaxis or hypersensitivity and five of those given into a vein, including a woman who had anaphylaxis, was given the drug again ten days later and needed resuscitation. Then there is endotoxin, the fragment of dead bacterial cell wall that survives sterilisation, which causes no infection but a violent reaction within minutes. Two clusters of seven patients each sit in the record and they are not the same event: seven cases of probable endotoxin poisoning in New South Wales, and seven patients at an American clinic in January 2019 who were ill within minutes of a 1,400 mg dose. A pharmacy in Austin, Texas then withdrew three lots of vials on 5 August 2026 for elevated endotoxin, with no published link to either. The Philippine regulator's 2019 advisory names toxic effects on the liver, kidneys and nervous system.